Trials / Terminated
TerminatedNCT00748410
Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis
An Open Label, 7-day Repeat Dose Study to Evaluate the Pharmacodynamics of SB-656933-AAA in Patients With Ulcerative Colitis.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will involve the use of a new compound, SB-656933. Accumulation of inflammatory white blood cells (mostly polymorphonuclear neutrophils)in the gut (colon) may be contributing to the pathology of ulcerative colitis. It has been shown that SB-656933 reduces polymorphonuclear neutrophils (PMN) accumulation in pre-clinical models of colitis. 99m-Tc-HMPAO scintigraphy is a imaging technique which will be used in this study to observe the effect of SB656933 on the migration of PMN to inflamed tissue.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SB-656933 | 7 days repeat dose |
Timeline
- Start date
- 2009-01-22
- Primary completion
- 2009-12-12
- Completion
- 2009-12-12
- First posted
- 2008-09-08
- Last updated
- 2020-10-30
- Results posted
- 2018-03-14
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00748410. Inclusion in this directory is not an endorsement.